SATISFACTION (2.27.2026) Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. https://t.co/IfbOUZV0dP https://t.co/nVxjdG8f26

IL-23i fails in GCA? Small RCT of 53 GCA pts (age 71 yrs; 60% new; 40% relapsing GCA) 35 given Guselkumab vs 18 on PBO. Wk 28 GC free remission in 40% vs 33% (P .64), also w/ similar flare rates (31% v 39%). results didnt supportguselkumab use in GCA. https://t.co/AMTmiDBc94 https://t.co/KdWTX9K2Bo

Diacerin, an IL-1β blocker, compared to placebo in a 262 pt RCT of knee pain, Knee #OA w/ inflammation. After 24 wks, 88% completed the trial & (vs PBO) diacerein did not improve knee pain (−19.9 vs −18.6 mm). 42% had AE/ GI Sxs were more w/ diacerein (42% vs 25% PBO https://t.co/QabS3xLN85

CDC study of Death certificate data showed that btw 2018–2023, there were 14,936 #SLE deaths (43% w/ SLE as the underlying cause). Mortality rate per million: females 5.97 > males 1.16, blacks 10.7. Causes of death:heart disease (0.93), cancer (0.56), COVID-19 (0.51). https://t.co/qTe6O66wRO

Cross-sectional study of Joint hypermobility (JH) in 256 young adults (75% female) found JH in 42%, females w/ signif. higher Beighton scores. 88% had chronic MSK pain; 38% had acute MSK pain. MSK pain was signif higher in students with mild JH (BS 4–6/9 pts; P < 0.009) https://t.co/QZwJ9zHfEj

BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi? Find out in the RheumNow poster hall with data from the latest real-world study of long-term RA remission. Sponsored by AbbVieMedical Affairs + Health Impact. https://t.co/PPYVfz3tuC https://t.co/Boq8V3qqFp

US Epidemiologic survey data from NHANES gout prevalence is incr. in RA pts vs controls (10.3% vs. 4.8%, P < 0.001), increasing trend over time. RA is as an independent risk factor for gout (OR: 2.67), strongest in SNRA. Evidence for the converse may not be as strong. https://t.co/VzDcJ2hTKw

Equivalent Healthcare Outcomes by Nurses and Physicians With increasing demand for health services in an aging population, serving complex patients with comorbidities, and increasing healthcare costs, the question of whether nurses can substitute for physicians was addressed by https://t.co/nKsFn7pUgw

OA & Exercise? Metanalysis of 5 reviews (n=8631) & 28 trials (n=4360) show little or no proof that exercise benefits OA. Exercise has small, short-term effects vs placebo & no-treatment for knee OA pain. Moderate evidence of no effects in hip, & small effects in hand OA. https://t.co/ycLGNlP8Sf

The prevalence of Systemic lupus erythematosus (SLE) in Australia is 26,788 (16,294 certain, 10,494 uncertain cases). Betw 2010-2022 incidence was 77-127/100,000 (certain cases). About half had received SLE care in an outpatient setting. Australia is 1/13 the population of USA https://t.co/n1sbFNPRbn

Full read review of JAK inhibitors. JAK inhibitors have a reasonably rapid onset of action and a short half-life, which facilitates management of any adverse effects. The half-life of Tofacitinib, Baricitinib & Upadacitinib is 3 hrs, 13 hrs. & 9-14hrs. https://t.co/C9t2SQ3Juq